Accelerating Innovations for Enhanced Brain Health. Can Artificial Intelligence Advance New Pathways for Drug Discovery for Alzheimer’s and other Neurodegenerative Disorders? A. S. KhachaturianA. DengelM. Tolar Editorial 05 January 2023 Pages: 1 - 4
Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness Jeffrey Cummings Editorial 09 December 2022 Pages: 5 - 6
Usefulness of Anchor Based Methods for Determining Clinically Meaningful Change in MCI due to AD Suzanne B. HendrixS. P. DicksonPentara Corporation Editorial 22 December 2022 Pages: 7 - 8
Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer’s Disease Claire J. LansdallF. McDougallR. S. Doody Original Research Open access 08 December 2022 Pages: 9 - 18
ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan Eric SiemersJ. HitchcockR. Barton Original Research Open access 26 October 2022 Pages: 19 - 24
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer’s and Parkinson’s Patients Cheng FangP. HernandezM. Maccecchini Original Research Open access 10 October 2022 Pages: 25 - 33
US Adults’ Likelihood to Participate in Dementia Prevention Drug Trials: Results from the National Poll on Healthy Aging Chelsea G. CoxM. A. DavisJ. S. Roberts Original Research 19 October 2022 Pages: 34 - 40
The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer’s Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Edmond TengP. T. ManserK. M. Sink Original Research Open access 22 November 2022 Pages: 41 - 49
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020 N. Navarro-GómezM. Valdes-GonzalezGabino Garrido Review 05 January 2023 Pages: 50 - 68
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials Andrea E. ZülkeS. G. Riedel-HellerM. Luppa Systematic Review Open access 22 November 2022 Pages: 69 - 82
Socioeconomic Status and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 39 Prospective Studies A.-Y. WangH.-Y. HuJin-Tai Yu Review 27 September 2022 Pages: 83 - 94
Programmed Death of Microglia in Alzheimer’s Disease: Autophagy, Ferroptosis, and Pyroptosis Z. QiuH. ZhangChanghong Miao Review 05 January 2023 Pages: 95 - 103
Age- and Sex-Different Associations between Cognitive Performance and Inflammatory Biomarkers in Community Dwelling Older Adults: towards Precision Preventive Strategies B.-A. ChenW.-J. LeeLiang-Kung Chen Original Research 06 October 2022 Pages: 104 - 111
Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer’s Disease Kellen K. PetersenA. EzzatiE. Grober Original Research 03 November 2022 Pages: 112 - 119
Systematic and Comparative Analysis of the Burden of Alzheimer’s Disease and Other Dementias in Mexico. Results at the National and Subnational Levels, 1990–2019 M. Agudelo-BoteroL. Giraldo-RodríguezMario E. Rojas-Russell Original Research Open access 26 October 2022 Pages: 120 - 129
Demographic Analysis of Industry-Sponsored Alzheimer’s Disease Trial Populations in the United States Stephen J. Peroutka Short Communication 20 October 2022 Pages: 130 - 132
Risk Estimates of Dementia and Alzheimer’s Disease among Different Whole Grain Food Consumption Categories: A Pilot Study Kanran WangQin Zhou Brief Reports 06 January 2023 Pages: 133 - 136
Prevention of Alzheimer’s Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference M. S. HersheyM. Sotos-PrietoN. Scarmeas Brief Report 03 November 2022 Pages: 137 - 143
Embryo Selection for a Carrier of an Early-Onset Alzheimer’s Disease-Associated Mutation in the PSEN1 Gene O. H. Valdés-MartínezS. M. García-LunaFelipe Arturo Morales-Martínez Brief Report 06 January 2023 Pages: 144 - 147
AMBAR: A Therapeutical Approach for Alzheimer’s Disease Patients Regardless of Amyloid Status Montserrat CostaM. Boada Letter to the Editor Open access 04 November 2022 Pages: 148 - 149
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats B. SouchetM. AudrainJérôme Braudeau Erratum 17 September 2022 Pages: 150 - 150
Erratum to: Alzheimer’s Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer’s Disease Suzanne B. HendrixH. SoininenT. Hartmann Erratum Open access 23 September 2019 Pages: 151 - 151
